Program
FXS0683
A development code.
In Fosun Pharma's pipeline, BCL-2
. Its studies are mostly in Lymphoma, B-Cell, led by Fosun Pharma.
Furthest: phase 1, since May 19, 20261 company-led study, 1 open or runningNext primary completion: Aug 7, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 11 open or running | phase 1since May 19, 2026 | May 19, 2026 | Aug 7, 2028phase 1 · NCT07616089 |
- Named in Fosun Pharma’s own pipeline as
FXS0683 (BCL-2)
, phase 1, as of Sep 21, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 19, 2026First study: phase 1 study in Lymphoma, B-CellFirst studyNCT07616089 · 228 planned · China
Ahead
- Aug 7, 2028Primary completion: phase 1 study in Lymphoma, B-CellNCT07616089
TargetBeta
“BCL-2”the company's pipeline, read by Claude · source
Other programs on BCL2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| venetoclaxrule | AbbVie | phase 4 | 83 |
| Bcl-2 Inhibitor TQB3909 | Sino Biopharmaceutical | phase 3 | 8 |
| lacutoclaxrule | Lupeng Pharmaceutical | phase 2 | 4 |
| surzetoclax | AbbVie | phase 2 | 3 |
| 400mg of TQB3909 tablets | Sino Biopharmaceutical | phase 2 | 1 |
| surzetoclax | AbbVie | phase 1 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07616089Lymphoma, B-Cell · China | 1 | Recruiting | Aug 7, 2028 | 228 |
How it is read
Names in the registry
- “FXS0683”, 1 entry
Codes read as this program: FXS0683.
Conditions, from the studies’ own filings
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.